Such a re-shaping of HSP90 inhibition, aimed at avoiding the deleterious effects of a global damage to cellular proteostasis, would imply selecting different agents for combination usage and reconsidering dosing strategies, adapting them to various cancer patient subsets (173). This evidence concerns the gene HSP90AA1 and cancer.